http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 14 Jul 2026 16:19:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Armata+Pharmaceuticals%2C+++For%3A+Jul+10++Filed+by%3A+Birx+Deborah/26768510.html si-local-file:///var/storage/secattach/20260714/26768510.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Armata+Pharmaceuticals%2C+++For%3A+Jul+10++Filed+by%3A+Birx+Deborah/26768510.html Tue, 14 Jul 2026 16:19:00 -0400 ARMP O.00168871 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Armata+Pharmaceuticals%2C+++For%3A+Jul+10++Filed+by%3A+Birx+Deborah/26768510.html si-local-file:///var/storage/secattach/20260714/26768510.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Armata+Pharmaceuticals%2C+++For%3A+Jul+10++Filed+by%3A+Birx+Deborah/26768510.html Tue, 14 Jul 2026 16:19:00 -0400 ARMP O.00168871 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Armata+Pharmaceuticals%2C+++For%3A+Jul+13/26759669.html si-local-file:///var/storage/secattach/20260713/26759669.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Armata+Pharmaceuticals%2C+++For%3A+Jul+13/26759669.html Mon, 13 Jul 2026 07:11:00 -0400 ARMP O.00168871 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Armata+Pharmaceuticals%2C+++For%3A+Jul+13/26759669.html si-local-file:///var/storage/secattach/20260713/26759669.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Armata+Pharmaceuticals%2C+++For%3A+Jul+13/26759669.html Mon, 13 Jul 2026 07:11:00 -0400 ARMP O.00168871 http://www.streetinsider.com/Corporate+News/FDA+agrees+to+Armata%27s+pediatric+study+plan+for+AP-SA02+bacteremia+drug/26759567.html <p>Armata Pharmaceuticals, Inc. (NYSE American: ARMP) announced it has received agreement from the U.S. Food and Drug Administration on an Agreed Initial Pediatric Study Plan for AP-SA02, its bacteriophage therapeutic candidate for the adjunct treatment of complicated <em>Staphylococcus aureus</em> bacteremia.</p><p>The agreement establishes a regulatory framework for evaluating AP-SA02 in pediatric patients up to 17 years of age. Under the Pediatric Research Equity Act, the FDA agreed that pediatric studies should be deferred until adult safety and efficacy data are generated, given that disease pathophysiology and treatment response in <em>S. aureus</em> bacteremia are consistent across age groups.</p><p>Following completion of the adult http://www.streetinsider.com/Corporate+News/FDA+agrees+to+Armata%27s+pediatric+study+plan+for+AP-SA02+bacteremia+drug/26759567.html Mon, 13 Jul 2026 07:00:52 -0400 ARMP http://www.streetinsider.com/FDA/FDA+agrees+to+Armata%27s+pediatric+study+plan+for+AP-SA02+bacteremia+drug/26759567.html <p>Armata Pharmaceuticals, Inc. (NYSE American: ARMP) announced it has received agreement from the U.S. Food and Drug Administration on an Agreed Initial Pediatric Study Plan for AP-SA02, its bacteriophage therapeutic candidate for the adjunct treatment of complicated <em>Staphylococcus aureus</em> bacteremia.</p><p>The agreement establishes a regulatory framework for evaluating AP-SA02 in pediatric patients up to 17 years of age. Under the Pediatric Research Equity Act, the FDA agreed that pediatric studies should be deferred until adult safety and efficacy data are generated, given that disease pathophysiology and treatment response in <em>S. aureus</em> bacteremia are consistent across age groups.</p><p>Following completion of the adult http://www.streetinsider.com/FDA/FDA+agrees+to+Armata%27s+pediatric+study+plan+for+AP-SA02+bacteremia+drug/26759567.html Mon, 13 Jul 2026 07:00:52 -0400 ARMP http://www.streetinsider.com/Press+Releases/Armata+Pharmaceuticals+Receives+Agreement+from+FDA+on+Initial+Pediatric+Study+Plan+for+AP-SA02+for+the+Treatment+of+Complicated+Staphylococcus+aureus+Bacteremia/26759524.html <div class="xn-content"> <p class="prntac"><i>Fulfills important regulatory milestone for AP-SA02 on the path toward a future BLA and supports expansion into pediatric patients</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.losang" idsrc="xmltag.org" >LOS ANGELES</location></span>, <span class="legendSpanClass"><chron>July 13, 2026</chron></span> /PRNewswire/ -- <span value="AMEX:ARMP" idsrc="xmltag.org" >Armata Pharmaceuticals, Inc.</span> (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced that it has received agreement from the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration</span> (the "FDA") on an Agreed Initial Pediatric Study Plan ("Agreed iPSP"), which establishes the agreed http://www.streetinsider.com/Press+Releases/Armata+Pharmaceuticals+Receives+Agreement+from+FDA+on+Initial+Pediatric+Study+Plan+for+AP-SA02+for+the+Treatment+of+Complicated+Staphylococcus+aureus+Bacteremia/26759524.html Mon, 13 Jul 2026 07:00:00 -0400 A.06822034 A.31066700 ARMP O.00168871 O.20026344 O.22422661 http://www.streetinsider.com/Press+Releases/Armata+Pharmaceuticals+Receives+Agreement+from+FDA+on+Initial+Pediatric+Study+Plan+for+AP-SA02+for+the+Treatment+of+Complicated+Staphylococcus+aureus+Bacteremia/26759524.html <div class="xn-content"> <p class="prntac"><i>Fulfills important regulatory milestone for AP-SA02 on the path toward a future BLA and supports expansion into pediatric patients</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.losang" idsrc="xmltag.org" >LOS ANGELES</location></span>, <span class="legendSpanClass"><chron>July 13, 2026</chron></span> /PRNewswire/ -- <span value="AMEX:ARMP" idsrc="xmltag.org" >Armata Pharmaceuticals, Inc.</span> (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced that it has received agreement from the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration</span> (the "FDA") on an Agreed Initial Pediatric Study Plan ("Agreed iPSP"), which establishes the agreed http://www.streetinsider.com/Press+Releases/Armata+Pharmaceuticals+Receives+Agreement+from+FDA+on+Initial+Pediatric+Study+Plan+for+AP-SA02+for+the+Treatment+of+Complicated+Staphylococcus+aureus+Bacteremia/26759524.html Mon, 13 Jul 2026 07:00:00 -0400 A.06822034 A.31066700 ARMP O.00168871 O.20026344 O.22422661 http://www.streetinsider.com/Press+Releases/Armata+Pharmaceuticals+Receives+Agreement+from+FDA+on+Initial+Pediatric+Study+Plan+for+AP-SA02+for+the+Treatment+of+Complicated+Staphylococcus+aureus+Bacteremia/26759524.html <div class="xn-content"> <p class="prntac"><i>Fulfills important regulatory milestone for AP-SA02 on the path toward a future BLA and supports expansion into pediatric patients</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.losang" idsrc="xmltag.org" >LOS ANGELES</location></span>, <span class="legendSpanClass"><chron>July 13, 2026</chron></span> /PRNewswire/ -- <span value="AMEX:ARMP" idsrc="xmltag.org" >Armata Pharmaceuticals, Inc.</span> (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced that it has received agreement from the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration</span> (the "FDA") on an Agreed Initial Pediatric Study Plan ("Agreed iPSP"), which establishes the agreed http://www.streetinsider.com/Press+Releases/Armata+Pharmaceuticals+Receives+Agreement+from+FDA+on+Initial+Pediatric+Study+Plan+for+AP-SA02+for+the+Treatment+of+Complicated+Staphylococcus+aureus+Bacteremia/26759524.html Mon, 13 Jul 2026 07:00:00 -0400 A.06822034 A.31066700 ARMP O.00168871 O.20026344 O.22422661 http://www.streetinsider.com/Press+Releases/Armata+Pharmaceuticals+Receives+Agreement+from+FDA+on+Initial+Pediatric+Study+Plan+for+AP-SA02+for+the+Treatment+of+Complicated+Staphylococcus+aureus+Bacteremia/26759524.html <div class="xn-content"> <p class="prntac"><i>Fulfills important regulatory milestone for AP-SA02 on the path toward a future BLA and supports expansion into pediatric patients</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.losang" idsrc="xmltag.org" >LOS ANGELES</location></span>, <span class="legendSpanClass"><chron>July 13, 2026</chron></span> /PRNewswire/ -- <span value="AMEX:ARMP" idsrc="xmltag.org" >Armata Pharmaceuticals, Inc.</span> (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced that it has received agreement from the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration</span> (the "FDA") on an Agreed Initial Pediatric Study Plan ("Agreed iPSP"), which establishes the agreed http://www.streetinsider.com/Press+Releases/Armata+Pharmaceuticals+Receives+Agreement+from+FDA+on+Initial+Pediatric+Study+Plan+for+AP-SA02+for+the+Treatment+of+Complicated+Staphylococcus+aureus+Bacteremia/26759524.html Mon, 13 Jul 2026 07:00:00 -0400 A.06822034 A.31066700 ARMP O.00168871 O.20026344 O.22422661 http://www.streetinsider.com/Press+Releases/Armata+Pharmaceuticals+Receives+Agreement+from+FDA+on+Initial+Pediatric+Study+Plan+for+AP-SA02+for+the+Treatment+of+Complicated+Staphylococcus+aureus+Bacteremia/26759524.html <div class="xn-content"> <p class="prntac"><i>Fulfills important regulatory milestone for AP-SA02 on the path toward a future BLA and supports expansion into pediatric patients</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.losang" idsrc="xmltag.org" >LOS ANGELES</location></span>, <span class="legendSpanClass"><chron>July 13, 2026</chron></span> /PRNewswire/ -- <span value="AMEX:ARMP" idsrc="xmltag.org" >Armata Pharmaceuticals, Inc.</span> (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced that it has received agreement from the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration</span> (the "FDA") on an Agreed Initial Pediatric Study Plan ("Agreed iPSP"), which establishes the agreed http://www.streetinsider.com/Press+Releases/Armata+Pharmaceuticals+Receives+Agreement+from+FDA+on+Initial+Pediatric+Study+Plan+for+AP-SA02+for+the+Treatment+of+Complicated+Staphylococcus+aureus+Bacteremia/26759524.html Mon, 13 Jul 2026 07:00:00 -0400 A.06822034 A.31066700 ARMP O.00168871 O.20026344 O.22422661 http://www.streetinsider.com/Press+Releases/Armata+Pharmaceuticals+Receives+Agreement+from+FDA+on+Initial+Pediatric+Study+Plan+for+AP-SA02+for+the+Treatment+of+Complicated+Staphylococcus+aureus+Bacteremia/26759524.html <div class="xn-content"> <p class="prntac"><i>Fulfills important regulatory milestone for AP-SA02 on the path toward a future BLA and supports expansion into pediatric patients</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.losang" idsrc="xmltag.org" >LOS ANGELES</location></span>, <span class="legendSpanClass"><chron>July 13, 2026</chron></span> /PRNewswire/ -- <span value="AMEX:ARMP" idsrc="xmltag.org" >Armata Pharmaceuticals, Inc.</span> (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced that it has received agreement from the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration</span> (the "FDA") on an Agreed Initial Pediatric Study Plan ("Agreed iPSP"), which establishes the agreed http://www.streetinsider.com/Press+Releases/Armata+Pharmaceuticals+Receives+Agreement+from+FDA+on+Initial+Pediatric+Study+Plan+for+AP-SA02+for+the+Treatment+of+Complicated+Staphylococcus+aureus+Bacteremia/26759524.html Mon, 13 Jul 2026 07:00:00 -0400 A.06822034 A.31066700 ARMP O.00168871 O.20026344 O.22422661 http://www.streetinsider.com/PRNewswire/Armata+Pharmaceuticals+Receives+Agreement+from+FDA+on+Initial+Pediatric+Study+Plan+for+AP-SA02+for+the+Treatment+of+Complicated+Staphylococcus+aureus+Bacteremia/26759524.html <div class="xn-content"> <p class="prntac"><i>Fulfills important regulatory milestone for AP-SA02 on the path toward a future BLA and supports expansion into pediatric patients</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.losang" idsrc="xmltag.org" >LOS ANGELES</location></span>, <span class="legendSpanClass"><chron>July 13, 2026</chron></span> /PRNewswire/ -- <span value="AMEX:ARMP" idsrc="xmltag.org" >Armata Pharmaceuticals, Inc.</span> (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced that it has received agreement from the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration</span> (the "FDA") on an Agreed Initial Pediatric Study Plan ("Agreed iPSP"), which establishes the agreed http://www.streetinsider.com/PRNewswire/Armata+Pharmaceuticals+Receives+Agreement+from+FDA+on+Initial+Pediatric+Study+Plan+for+AP-SA02+for+the+Treatment+of+Complicated+Staphylococcus+aureus+Bacteremia/26759524.html Mon, 13 Jul 2026 07:00:00 -0400 A.06822034 A.31066700 ARMP O.00168871 O.20026344 O.22422661 http://www.streetinsider.com/PRNewswire/Armata+Pharmaceuticals+Receives+Agreement+from+FDA+on+Initial+Pediatric+Study+Plan+for+AP-SA02+for+the+Treatment+of+Complicated+Staphylococcus+aureus+Bacteremia/26759524.html <div class="xn-content"> <p class="prntac"><i>Fulfills important regulatory milestone for AP-SA02 on the path toward a future BLA and supports expansion into pediatric patients</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.losang" idsrc="xmltag.org" >LOS ANGELES</location></span>, <span class="legendSpanClass"><chron>July 13, 2026</chron></span> /PRNewswire/ -- <span value="AMEX:ARMP" idsrc="xmltag.org" >Armata Pharmaceuticals, Inc.</span> (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced that it has received agreement from the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration</span> (the "FDA") on an Agreed Initial Pediatric Study Plan ("Agreed iPSP"), which establishes the agreed http://www.streetinsider.com/PRNewswire/Armata+Pharmaceuticals+Receives+Agreement+from+FDA+on+Initial+Pediatric+Study+Plan+for+AP-SA02+for+the+Treatment+of+Complicated+Staphylococcus+aureus+Bacteremia/26759524.html Mon, 13 Jul 2026 07:00:00 -0400 A.06822034 A.31066700 ARMP O.00168871 O.20026344 O.22422661 http://www.streetinsider.com/PRNewswire/Armata+Pharmaceuticals+Receives+Agreement+from+FDA+on+Initial+Pediatric+Study+Plan+for+AP-SA02+for+the+Treatment+of+Complicated+Staphylococcus+aureus+Bacteremia/26759524.html <div class="xn-content"> <p class="prntac"><i>Fulfills important regulatory milestone for AP-SA02 on the path toward a future BLA and supports expansion into pediatric patients</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.losang" idsrc="xmltag.org" >LOS ANGELES</location></span>, <span class="legendSpanClass"><chron>July 13, 2026</chron></span> /PRNewswire/ -- <span value="AMEX:ARMP" idsrc="xmltag.org" >Armata Pharmaceuticals, Inc.</span> (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced that it has received agreement from the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration</span> (the "FDA") on an Agreed Initial Pediatric Study Plan ("Agreed iPSP"), which establishes the agreed http://www.streetinsider.com/PRNewswire/Armata+Pharmaceuticals+Receives+Agreement+from+FDA+on+Initial+Pediatric+Study+Plan+for+AP-SA02+for+the+Treatment+of+Complicated+Staphylococcus+aureus+Bacteremia/26759524.html Mon, 13 Jul 2026 07:00:00 -0400 A.06822034 A.31066700 ARMP O.00168871 O.20026344 O.22422661 http://www.streetinsider.com/PRNewswire/Armata+Pharmaceuticals+Receives+Agreement+from+FDA+on+Initial+Pediatric+Study+Plan+for+AP-SA02+for+the+Treatment+of+Complicated+Staphylococcus+aureus+Bacteremia/26759524.html <div class="xn-content"> <p class="prntac"><i>Fulfills important regulatory milestone for AP-SA02 on the path toward a future BLA and supports expansion into pediatric patients</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.losang" idsrc="xmltag.org" >LOS ANGELES</location></span>, <span class="legendSpanClass"><chron>July 13, 2026</chron></span> /PRNewswire/ -- <span value="AMEX:ARMP" idsrc="xmltag.org" >Armata Pharmaceuticals, Inc.</span> (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced that it has received agreement from the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration</span> (the "FDA") on an Agreed Initial Pediatric Study Plan ("Agreed iPSP"), which establishes the agreed http://www.streetinsider.com/PRNewswire/Armata+Pharmaceuticals+Receives+Agreement+from+FDA+on+Initial+Pediatric+Study+Plan+for+AP-SA02+for+the+Treatment+of+Complicated+Staphylococcus+aureus+Bacteremia/26759524.html Mon, 13 Jul 2026 07:00:00 -0400 A.06822034 A.31066700 ARMP O.00168871 O.20026344 O.22422661 http://www.streetinsider.com/PRNewswire/Armata+Pharmaceuticals+Receives+Agreement+from+FDA+on+Initial+Pediatric+Study+Plan+for+AP-SA02+for+the+Treatment+of+Complicated+Staphylococcus+aureus+Bacteremia/26759524.html <div class="xn-content"> <p class="prntac"><i>Fulfills important regulatory milestone for AP-SA02 on the path toward a future BLA and supports expansion into pediatric patients</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.losang" idsrc="xmltag.org" >LOS ANGELES</location></span>, <span class="legendSpanClass"><chron>July 13, 2026</chron></span> /PRNewswire/ -- <span value="AMEX:ARMP" idsrc="xmltag.org" >Armata Pharmaceuticals, Inc.</span> (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced that it has received agreement from the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration</span> (the "FDA") on an Agreed Initial Pediatric Study Plan ("Agreed iPSP"), which establishes the agreed http://www.streetinsider.com/PRNewswire/Armata+Pharmaceuticals+Receives+Agreement+from+FDA+on+Initial+Pediatric+Study+Plan+for+AP-SA02+for+the+Treatment+of+Complicated+Staphylococcus+aureus+Bacteremia/26759524.html Mon, 13 Jul 2026 07:00:00 -0400 A.06822034 A.31066700 ARMP O.00168871 O.20026344 O.22422661 http://www.streetinsider.com/PRNewswire/Armata+Pharmaceuticals+Receives+Agreement+from+FDA+on+Initial+Pediatric+Study+Plan+for+AP-SA02+for+the+Treatment+of+Complicated+Staphylococcus+aureus+Bacteremia/26759524.html <div class="xn-content"> <p class="prntac"><i>Fulfills important regulatory milestone for AP-SA02 on the path toward a future BLA and supports expansion into pediatric patients</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.losang" idsrc="xmltag.org" >LOS ANGELES</location></span>, <span class="legendSpanClass"><chron>July 13, 2026</chron></span> /PRNewswire/ -- <span value="AMEX:ARMP" idsrc="xmltag.org" >Armata Pharmaceuticals, Inc.</span> (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced that it has received agreement from the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration</span> (the "FDA") on an Agreed Initial Pediatric Study Plan ("Agreed iPSP"), which establishes the agreed http://www.streetinsider.com/PRNewswire/Armata+Pharmaceuticals+Receives+Agreement+from+FDA+on+Initial+Pediatric+Study+Plan+for+AP-SA02+for+the+Treatment+of+Complicated+Staphylococcus+aureus+Bacteremia/26759524.html Mon, 13 Jul 2026 07:00:00 -0400 A.06822034 A.31066700 ARMP O.00168871 O.20026344 O.22422661 http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++Armata+Pharmaceuticals%2C++++++++++++++/26759130.html si-local-file:///var/storage/secattach/20260713/26759130.html http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++Armata+Pharmaceuticals%2C++++++++++++++/26759130.html Mon, 13 Jul 2026 06:02:00 -0400 ARMP O.00168871 http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++Armata+Pharmaceuticals%2C++++++++++++++/26759130.html si-local-file:///var/storage/secattach/20260713/26759130.html http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++Armata+Pharmaceuticals%2C++++++++++++++/26759130.html Mon, 13 Jul 2026 06:02:00 -0400 ARMP O.00168871 http://www.streetinsider.com/SEC+Filings/Form++8-KA++++++Armata+Pharmaceuticals%2C+++For%3A+Apr+24/26685794.html si-local-file:///var/storage/secattach/20260624/26685794.html http://www.streetinsider.com/SEC+Filings/Form++8-KA++++++Armata+Pharmaceuticals%2C+++For%3A+Apr+24/26685794.html Wed, 24 Jun 2026 16:19:00 -0400 ARMP O.00168871 http://www.streetinsider.com/SEC+Filings/Form++8-KA++++++Armata+Pharmaceuticals%2C+++For%3A+Apr+24/26685794.html si-local-file:///var/storage/secattach/20260624/26685794.html http://www.streetinsider.com/SEC+Filings/Form++8-KA++++++Armata+Pharmaceuticals%2C+++For%3A+Apr+24/26685794.html Wed, 24 Jun 2026 16:19:00 -0400 ARMP O.00168871 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Armata+Pharmaceuticals%2C+++For%3A+Jun+23/26675761.html si-local-file:///var/storage/secattach/20260623/26675761.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Armata+Pharmaceuticals%2C+++For%3A+Jun+23/26675761.html Tue, 23 Jun 2026 07:11:00 -0400 ARMP O.00168871 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Armata+Pharmaceuticals%2C+++For%3A+Jun+23/26675761.html si-local-file:///var/storage/secattach/20260623/26675761.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Armata+Pharmaceuticals%2C+++For%3A+Jun+23/26675761.html Tue, 23 Jun 2026 07:11:00 -0400 ARMP O.00168871 http://www.streetinsider.com/Corporate+News/Armata+gets+%242.5M+more+in+DoD+funding+for+bacteriophage+drug/26675711.html <p>Armata Pharmaceuticals (NYSE American: ARMP) announced it has received an additional $2.5 million in non-dilutive funding from the U.S. Department of Defense (DoD) to support the development of its lead clinical candidate AP-SA02, a bacteriophage therapeutic targeting <i>Staphylococcus aureus</i> bacteremia.</p><p>The funding was received through the Medical Technology Enterprise Consortium and is managed by the Naval Medical Research Command with contributions from the Defense Health Agency and Joint Warfighter Medical Research Program. Total non-dilutive DoD funding for the program now stands at $28.7 million.</p><p>The additional $2.5 million is designated to fund activities supporting Phase 3 readiness of AP-SA02, which Armata plans http://www.streetinsider.com/Corporate+News/Armata+gets+%242.5M+more+in+DoD+funding+for+bacteriophage+drug/26675711.html Tue, 23 Jun 2026 07:01:23 -0400 ARMP